{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:43:07Z","timestamp":1789411387028,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Because of recent reports of praziquantel resistance in schistosome infections, there have been suggestions to employ ivermectin as a possible alternative, especially as its chemical composition is different from that of praziquantel, so cross-resistance is not expected. In order to ascertain possible damage and elimination of worms, we used ivermectin by oral gavage in infected mice, at a high dose (30.1 mg\/kg, bordering toxicity). We also tested the efficacy of the drug at various times postinfection (PI), to check on possible effect on young and mature stages of the parasites. Thus, we treated mice on days 21 and 22 or on days 41 and 42 and even on days 21, 22, 41, and 42 PI. None of the treatment regimens resulted in cure rates or signs of lessened pathology in the mice. We also compared the effect of ivermectin to that of artemisone, an artemisinin derivative which had served us in the past as an effective anti-schistosome drug, and there was a stark difference in the artemisone\u2019s efficacy compared to that of ivermectin; while ivermectin was not effective, artemisone eliminated most of the worms, prevented egg production and granulomatous inflammatory response. We assume that the reported lack of activity of ivermectin, in comparison with praziquantel and artemisinins, originates from the difference in their mode of action. In wake of our results, we suggest that ivermectin is not a suitable drug for treatment of schistosomiasis.<\/jats:p>","DOI":"10.1007\/s00436-024-08178-1","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T06:01:31Z","timestamp":1712642491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Considering ivermectin for treatment of schistosomiasis"],"prefix":"10.1007","volume":"123","author":[{"given":"Jacob","family":"Golenser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Birman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"12","key":"8178_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010064","volume":"202117","author":"S Acharya","year":"2021","unstructured":"Acharya S, Da\u2019daraSkelly AAPJ (2021) Schistosome immunomodulators. PLoS Pathog 202117(12):e1010064","journal-title":"PLoS Pathog"},{"key":"8178_CR2","first-page":"156","volume":"2","author":"H Agere","year":"2014","unstructured":"Agere H, Kela SL, Istifanus WA (2014) Chemotherapeutic trials of praziquantel and ivermectin on victims of urinary schistosomiasis in Taraba North Senatorial District; Nigeria. Sci-Afric J Sci Issues Res Essays 2:156\u2013159","journal-title":"Sci-Afric J Sci Issues Res Essays"},{"issue":"7","key":"8178_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011018","volume":"19","author":"SN Alwan","year":"2023","unstructured":"Alwan SN, Taylor AB, Rhodes J et al (2023) Oxamniquine derivatives overcome praziquantel treatment limitations for schistosomiasis. PLoS Pathog 19(7):e1011018","journal-title":"PLoS Pathog"},{"key":"8178_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/1871526519666181231153139","volume":"19","author":"RT Aruleba","year":"2019","unstructured":"Aruleba RT, Adekiya TA, Oyinloye BE et al (2019) PZQ Therapy: how close are we in the development of effective alternative anti-schistosomal drugs? Infect Disord Drug Targets 19:337\u2013349","journal-title":"Infect Disord Drug Targets"},{"issue":"9","key":"8178_CR5","doi-asserted-by":"publisher","first-page":"e0005008","DOI":"10.1371\/journal.pntd.0005008","volume":"10","author":"B Barda","year":"2016","unstructured":"Barda B, Coulibaly JT, Puchkov M et al (2016) (2016) Efficacy and safety of moxidectin, synriam, synriam-praziquantel versus praziquantel against Schistosoma haematobium and S mansoni infections: a randomized, exploratory phase 2 trial. PLoS Negl Trop Dis. 10(9):e0005008","journal-title":"PLoS Negl Trop Dis."},{"key":"8178_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115179","volume":"251","author":"M Beutler","year":"2023","unstructured":"Beutler M, Harnischfeger J, Weber MHW et al (2023) Identification and characterisation of the tegument-expressed aldehyde dehydrogenase SmALDH_312 of Schistosoma mansoni, a target of disulfiram. Eur J Med Chem 251:115179","journal-title":"Eur J Med Chem"},{"key":"8178_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2460\/ajvr.1991.52.04.593","volume":"52","author":"BR Blakley","year":"1991","unstructured":"Blakley BR, Rousseux CG (1991) Effect of ivermectin on the immune response in mice. Am J Vet Res 52:593\u2013595","journal-title":"Am J Vet Res"},{"key":"8178_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2020.105677","volume":"218","author":"NW Brattig","year":"2021","unstructured":"Brattig NW, Cheke RA, Garms R (2021) Onchocerciasis (river blindness) - more than a century of research and control. Acta Trop 218:105677","journal-title":"Acta Trop"},{"key":"8178_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0014-4894(90)90028-B","volume":"71","author":"PJ Brindley","year":"1990","unstructured":"Brindley PJ, Sher A (1990) Immunological involvement in the efficacy of praziquantel. Exp Parasitol 71:245\u2013248","journal-title":"Exp Parasitol"},{"key":"8178_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1021\/acsinfecdis.3c00081","volume":"9","author":"N Caldwell","year":"2023","unstructured":"Caldwell N, Afshar R, Baraga\u00f1a B et al (2023) Perspective on schistosomiasis drug discovery: highlights from a schistosomiasis drug discovery workshop at Wellcome Collection. London, ACS Infect Dis 9:1046\u20131055","journal-title":"London, ACS Infect Dis"},{"key":"8178_CR11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1113\/JP275236","volume":"596","author":"IS Chen","year":"2018","unstructured":"Chen IS, Kubo Y (2018) Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin. J Physiol 596:1833\u20131845","journal-title":"J Physiol"},{"key":"8178_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijpara.2022.11.005","volume":"53","author":"EG Chulkov","year":"2023","unstructured":"Chulkov EG, Palygin O, Yahya NA (2023) Electrophysiological characterization of a schistosome transient receptor potential channel activated by praziquantel. Int J Parasitol 53:415\u2013425","journal-title":"Int J Parasitol"},{"key":"8178_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/BF02231085","volume":"6","author":"AB Coutinho","year":"1961","unstructured":"Coutinho AB (1961) Bilharzian liver fibrosis. Am J Dig Dis 6:887\u2013898","journal-title":"Am J Dig Dis"},{"issue":"20","key":"8178_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0024-3205(97)00144-6","volume":"60","author":"VM Cunha","year":"1997","unstructured":"Cunha VM, No\u00ebl F (1997) Praziquantel has no direct effect on (Na(+)+K+)-ATPases and (Ca2(+)-Mg2+)ATPases of Schistosoma mansoni. Life Sci. 60(20):289\u201394","journal-title":"Life Sci."},{"key":"8178_CR15","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1016\/j.bmc.2017.04.031","volume":"25","author":"VBR Da Silva","year":"2017","unstructured":"Da Silva VBR, Campos BRKL, de Oliveira JF et al (2017) Medicinal chemistry of anti-schistosomal drugs: praziquantel and oxamniquine. Bioorganic Med Chem 25:3259\u20133277","journal-title":"Bioorganic Med Chem"},{"issue":"11","key":"8178_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112163","volume":"9","author":"L Dong","year":"2014","unstructured":"Dong L, Duan W, Chen J et al (2014) An artemisinin derivative of praziquantel as an orally active antischistosomal agent. PLoSONE 9(11):e112163","journal-title":"PLoSONE"},{"key":"8178_CR17","doi-asserted-by":"crossref","unstructured":"Feng XP, Hayashi J, Beech RN et al (2002) Study of the nematode putative GABA type-A receptor subunits: evidence for modulation by ivermectin. J Neurochem 83:870\u2013878","DOI":"10.1046\/j.1471-4159.2002.01199.x"},{"key":"8178_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2020.151906","volume":"225","author":"SH Huang","year":"2020","unstructured":"Huang SH, Wu CH, Chen SJ et al (2020) Immunomodulatory effects and potential clinical applications of dimethyl sulfoxide. Immunobiolog 225:151906","journal-title":"Immunobiolog"},{"key":"8178_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/15563650.2022.2043338","volume":"60","author":"Johnson-Arbor,","year":"2022","unstructured":"Johnson-Arbor, (2022) Ivermectin: a mini-review. Clin Toxicol (phila) 60:571\u2013575","journal-title":"Clin Toxicol (phila)"},{"key":"8178_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/ja.2017.31","volume":"70","author":"N Katz","year":"2017","unstructured":"Katz N, Ara\u00fajo N, Coelho P et al (2017) Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of schistosomiasis. J Antibiot 70:680\u2013684","journal-title":"J Antibiot"},{"key":"8178_CR21","first-page":"3531","volume":"18","author":"J Keiser","year":"2012","unstructured":"Keiser J, Utzinger J (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18:3531\u20133538","journal-title":"Curr Pharm Des"},{"key":"8178_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/trstmh\/trab114","volume":"116","author":"C Kositz","year":"2022","unstructured":"Kositz C, Bradley J, Hutchins H et al (2022) Broadening the range of use cases for ivermectin \u2013 a review of the evidence. Trans R Soc Trop Med Hyg 116:201\u2013212","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"8178_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","volume":"33","author":"R Laing","year":"2017","unstructured":"Laing R, Gillan V, Devaney E (2017) Ivermectin \u2013 old drug, new tricks? Trends Parasitol 33:463\u2013472","journal-title":"Trends Parasitol"},{"key":"8178_CR24","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1126\/scitranslmed.abj9114","volume":"13","author":"W Le Clec\u2019h","year":"2021","unstructured":"Le Clec\u2019h W, Chevalier FD, Mattos ACA (2021) Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channel. Sci Transl Med. 13:9114","journal-title":"Sci Transl Med."},{"key":"8178_CR25","first-page":"28","volume":"2000","author":"WH Makunde","year":"2000","unstructured":"Makunde WH, Msangeni HA, Massaga JJ (2000) Assessment of the efficacy of ivermectin in the treatment of human intestinal helminths and urinary trematode infections in North-East Tanzania. Tanzan Health Res Bull 2000:28\u201330","journal-title":"Tanzan Health Res Bull"},{"key":"8178_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pt.2020.10.005","volume":"37","author":"RJ Martin","year":"2021","unstructured":"Martin RJ, Robertson AP, Choudhary S (2021) Ivermectin: an anthelmintic, an insecticide, and much more. Trends Parasitol 37:48\u201364","journal-title":"Trends Parasitol"},{"key":"8178_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635869","volume":"12","author":"PA Mawa","year":"2021","unstructured":"Mawa PA, Kincaid-Smith J, Tukahebwa EM et al (2021) Schistosomiasis morbidity hotspots: roles of the human host, the parasite and their interface in the development of severe morbidity. Front Immunol 12:635869","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"8178_CR28","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/0035-9203(94)90468-5","volume":"88","author":"SR Meshnick","year":"1994","unstructured":"Meshnick SR (1994) The mode of action of antimalarial endoperoxides. Trans Roy Soc Trop Med Hyg 88(Suppl 1):S31\u2013S32","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"8178_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.913301","volume":"12","author":"BP Moreira","year":"2022","unstructured":"Moreira BP, Batista ICA, Tavares NC et al (2022) Docking-based virtual screening enables prioritizing protein kinase inhibitors with in vitro phenotypic activity against Schistosoma mansoni. Front Cell Infect Microbiol 12:913301","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"8178_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619776","volume":"22","author":"Y Mu","year":"2021","unstructured":"Mu Y, McManus DP, Hou N, Cai P (2021) Schistosome infection and schistosome-derived products as modulators for the prevention and alleviation of immunological disorders. Front Immunol 22(12):619776","journal-title":"Front Immunol"},{"key":"8178_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4269\/ajtmh.1993.48.652","volume":"48","author":"FL Njoo","year":"1993","unstructured":"Njoo FL, Belling GA, Oosting J et al (1993) (1993) Concurrent parasitic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment. Am J Trop Med Hyg 48:652\u2013657","journal-title":"Am J Trop Med Hyg"},{"key":"8178_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2022.111531","volume":"252","author":"RA Nogueira","year":"2022","unstructured":"Nogueira RA, Lira MGS, Lic\u00e1 ICL et al (2022) Praziquantel: an update on the mechanism of its action against schistosomiasis and new therapeutic perspectives. Mol Biochem Parasitol 252:111531","journal-title":"Mol Biochem Parasitol"},{"key":"8178_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/1568026620666200924115113","volume":"21","author":"NF Oliveira","year":"2021","unstructured":"Oliveira NF (2021) Silva CLM (2021) Unveiling the potential of purinergic signaling in schistosomiasis treatment. Curr Top Med Chem 21:193\u2013204","journal-title":"Curr Top Med Chem"},{"issue":"625","key":"8178_CR34","doi-asserted-by":"publisher","first-page":"eabj5832","DOI":"10.1126\/scitranslmed.abj5832","volume":"13","author":"SK Park","year":"2021","unstructured":"Park SK, Friedrich L, Yahya NA et al (2021) Mechanism of praziquantel action at a parasitic flatworm ion channel. Sci Transl Med. 13(625):eabj5832","journal-title":"Sci Transl Med."},{"issue":"9","key":"8178_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/vetsci9010024","volume":"2022","author":"C Piras","year":"2022","unstructured":"Piras C, Gugliandolo E, Fabio, et al (2022) Ivermectin (IVM) possible side activities and implications in antimicrobial resistance and animal welfare: the authors\u2019 perspective. Vet Sci 2022(9):24","journal-title":"Vet Sci"},{"key":"8178_CR36","doi-asserted-by":"crossref","unstructured":"Quadros HC, Silva MCB, Moreira DRM (2022) The role of the iron protoporphyrins heme and hematin in the antimalarial activity of endoperoxide drugs. Pharmaceuticals (Basel, Switzerland) 15(1):60","DOI":"10.3390\/ph15010060"},{"issue":"3","key":"8178_CR37","doi-asserted-by":"publisher","first-page":"e0003593","DOI":"10.1371\/journal.pntd.0003593","volume":"9","author":"N Reimers","year":"2015","unstructured":"Reimers N, Homann A, H\u00f6schler B et al (2015) Drug-induced exposure of Schistosoma mansoni antigens SmCD59a and SmKK7. PLoS Negl Trop Dis. 9(3):e0003593","journal-title":"PLoS Negl Trop Dis."},{"key":"8178_CR38","doi-asserted-by":"crossref","unstructured":"Roquini V, Mengarda AC, Cajas RA et al (2023) The existing drug nifuroxazide as an anti-schistosomal agent: in vitro, in vivo, and in silico studies of macromolecular targets. Microbiol Spectr 11(4):e0139323","DOI":"10.1128\/spectrum.01393-23"},{"key":"8178_CR39","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01230-22","volume":"67","author":"KT Ryan","year":"2023","unstructured":"Ryan KT, Wheeler NJ, Kamara IK (2023) Phenotypic profiling of macrocyclic lactones on parasitic schistosoma flatworms. Antimicrob Agents Chemother 67:e0123022","journal-title":"Antimicrob Agents Chemother"},{"issue":"21","key":"8178_CR40","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.lfs.2007.02.025","volume":"80","author":"MS Sajid","year":"2007","unstructured":"Sajid MS, Iqbal Z, Muhammad G, Sandhu MA et al (2007) Effect of ivermectin on the cellular and humoral immune responses of rabbits. Life Sci 80(21):1966\u20131970","journal-title":"Life Sci"},{"key":"8178_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2172-5-6","volume":"5","author":"MZ Satti","year":"2004","unstructured":"Satti MZ, Cahen P, Skov PS, Joseph S et al (2004) Changes in IgE- and antigen-dependent histamine-release in peripheral blood of Schistosoma mansoni- infected Ugandan fishermen after treatment with praziquantel. BMC Immunol 5:6","journal-title":"BMC Immunol"},{"key":"8178_CR42","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2023-0006","author":"A Shafiee","year":"2023","unstructured":"Shafiee A, Teymouri Athar MM et al (2023) A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease? Future Virol. https:\/\/doi.org\/10.2217\/fvl-2023-0006","journal-title":"Future Virol"},{"key":"8178_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.exppara.2011.01.016","volume":"128","author":"F Shariati","year":"2011","unstructured":"Shariati F, P\u00e9rez-Arellano JL, Carranza C, L\u00f3pez-Ab\u00e1n J, Vicente B, Arefi M, Muro A (2011) Evaluation of the role of angiogenic factors in the pathogenesis of schistosomiasis. Exp Parasitol 128:44\u201349","journal-title":"Exp Parasitol"},{"key":"8178_CR44","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/medicina57101058","volume":"57","author":"AJ Siddiqui","year":"2021","unstructured":"Siddiqui AJ, Khan MF, Hamadou WS et al (2021) Molecular docking and dynamics simulation revealed ivermectin as potential drug against schistosoma-associated bladder cancer targeting protein signaling: computational drug repositioning approach. Medicina (kaunas) 57:1058","journal-title":"Medicina (kaunas)"},{"key":"8178_CR45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/acsinfecdis.0c00542","volume":"7","author":"T Spanbenberg","year":"2021","unstructured":"Spanbenberg T (2021) Alternatives to praziquantel for the prevention and control of schistosomiasis. ACS Infect Dis 7:939\u2013942","journal-title":"ACS Infect Dis"},{"key":"8178_CR46","first-page":"817","volume":"2","author":"A Taman","year":"2014","unstructured":"Taman A, El-Beshbishi S, El-Tantawy N et al (2014) Evaluation of the in vivo effect of ivermectin on Schistosoma mansoni in experimentally-infected mice. J. Coast Life Med 2:817\u2013823 (https:\/\/www.researchgate.net\/publication\/263466782)","journal-title":"J. Coast Life Med"},{"key":"8178_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02582-16","volume":"61","author":"N Vale","year":"2017","unstructured":"Vale N, Gouveia MJ, Rinaldi G et al (2017) Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother 61:1\u201316","journal-title":"Antimicrob Agents Chemother"},{"key":"8178_CR48","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1038\/s41598-021-84009-y","volume":"11","author":"B Vicente","year":"2021","unstructured":"Vicente B, L\u00f3pez-Ab\u00e1n J, Chaccour J et al (2021) The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice. Sci Rep 11:4476","journal-title":"Sci Rep"},{"key":"8178_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300154","volume":"18","author":"A Waechtler","year":"2023","unstructured":"Waechtler A, Cezanne B, Maillard D et al (2023) Praziquantel - 50 years of research. ChemMedChem 18:e202300154","journal-title":"ChemMedChem"},{"key":"8178_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/0035-9203(91)90037-Y","volume":"85","author":"JA Whitworth","year":"1991","unstructured":"Whitworth JA, Morgan D, Maude GH et al (1991) A field study of the effect of ivermectin on intestinal helminths in man. Trans R Soc Trop Med Hyg 85:232\u2013234","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"8178_CR51","unstructured":"WHO (2023) Schistosomiasis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis"},{"key":"8178_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12060509","volume":"12","author":"J Zech","year":"2020","unstructured":"Zech J, Gold D, Salaymeh N, Sasson NC et al (2020) Oral administration of artemisone for the treatment of schistosomiasis: formulation challenges and in vivo efficacy. Pharmaceutics 12:1\u201317","journal-title":"Pharmaceutics"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-024-08178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00436-024-08178-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-024-08178-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T08:03:35Z","timestamp":1715328215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00436-024-08178-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["8178"],"URL":"https:\/\/doi.org\/10.1007\/s00436-024-08178-1","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was approved by the Ethics Committee of Tel-Aviv University (# 01\u201313-076).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}